Marcum Wealth LLC raised its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,716 shares of the company’s stock after purchasing an additional 89 shares during the period. Marcum Wealth LLC’s holdings in Johnson & Johnson were worth $2,932,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. increased its holdings in Johnson & Johnson by 1.4% in the first quarter. BlackRock Inc. now owns 201,491,567 shares of the company’s stock valued at $31,231,193,000 after buying an additional 2,688,798 shares during the last quarter. Moneta Group Investment Advisors LLC grew its position in shares of Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after acquiring an additional 54,326,454 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Johnson & Johnson by 1.6% in the 1st quarter. Geode Capital Management LLC now owns 48,707,500 shares of the company’s stock valued at $7,532,525,000 after acquiring an additional 748,917 shares during the last quarter. Morgan Stanley lifted its stake in Johnson & Johnson by 12.0% during the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after purchasing an additional 4,521,062 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Johnson & Johnson by 15.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after purchasing an additional 3,849,148 shares during the period. 68.40% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Trading Down 0.7 %
Johnson & Johnson stock opened at $160.50 on Monday. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $181.04. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88. The stock has a market capitalization of $417.13 billion, a PE ratio of 32.49, a price-to-earnings-growth ratio of 3.25 and a beta of 0.54. The firm has a 50 day simple moving average of $166.51 and a 200-day simple moving average of $162.06.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were issued a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 2.97%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s payout ratio is 96.36%.
Insider Transactions at Johnson & Johnson
In related news, insider William Hait sold 14,698 shares of the stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at $15,092,484. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the company’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares of the company’s stock, valued at $15,092,484. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.
Analyst Ratings Changes
A number of analysts have weighed in on JNJ shares. HSBC started coverage on shares of Johnson & Johnson in a report on Wednesday, September 6th. They set a “hold” rating and a $175.00 target price on the stock. JPMorgan Chase & Co. raised their target price on shares of Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Atlantic Securities increased their price target on Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research report on Friday, August 4th. Barclays reduced their price objective on Johnson & Johnson from $175.00 to $158.00 and set an “equal weight” rating for the company in a research report on Friday, September 8th. Finally, Raymond James dropped their target price on Johnson & Johnson from $184.00 to $179.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 5th. Nine research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, Johnson & Johnson has an average rating of “Hold” and a consensus price target of $170.65.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 3 Reasons This Sleeping Giant Is About To Wake Up
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- MarketBeat Week in Review – 9/18 – 9/22
- Dividend Tax Calculator
- 52-week Low Names To Tip The Upside Scale In Your Favor
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
